Invest in MJ Blog

Invest In MJ is a multi-author and community member blog. Read the latest blogs about investment ideas in the marijuana and cannabis industry.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
Subscribe to this list via RSS Blog posts tagged in Medical Marijuana

August 5, 2015 

Pennsylvania drugmaker Zynerba Pharmaceuticals ($ZYNE) is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.

The company priced 3 million shares at $14 each, the middle of its range, and set aside another 450,000 shares for its underwriters to line up for as much as $51.8 million in total.

With the proceeds, Zynerba will press forward with a pair of early-stage transdermal patches that mete out cannabinoid chemicals to treat a host of CNS ailments. ZYN002, slated to enter clinical trials in the second half, has shown promise in refractory epilepsy, Fragile X syndrome and osteoarthritis pain, the company said. And ZYN001, in line for Phase I next year, targets fibromyalgia and peripheral neuropathic pain.

The promise of cannabis-derived pharmaceuticals has drawn a slew of companies to the field over the past few years, including GW Pharmaceuticals ($GWPH) and Insys Therapeutics ($INSY). But unlike its further-along competitors, Zynerba's treatments are synthetically manufactured and don't require growing and maintaining cannabis plants, which the company bills as a practical and financial advantage. Furthermore, Zynerba's transdermal therapies get their active ingredients straight into the circulatory system, avoiding the bioavailability issues that can plague oral treatments that must first navigate the stomach and liver.

Zynerba is led by CEO Armando Anido, appointed in 2014 after stints at the helm of Auxilium Pharmaceuticals, acquired by Endo Pharmaceutical ($ENDP) for about $2.6 billion, and NuPathe, which went to Teva ($TEVA) for $144 million last year.

Meanwhile, biotech's ongoing IPO boom has continued unabated into the second half of 2015, marked by a record debut for Patrick Soon-Shiong's NantKwest ($NK). And the queue of drug developers angling to go public remains full, as Zynerba joins a group including gene therapy outfit Gensight Biologics and food allergy biotech Aimmune Therapeutics.

The original post can be seen here.

Rate this blog entry:
0

LAS VEGASMay 27, 2015 /PRNewswire/ -- DigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (OTCQB: DIGPD) opened the doors of its Las Vegas marijuana analytical testing laboratory for business today. Equipped with state of the art analytical instrumentation and operated under the direction of Cindy Orser, PhD, DigiPath Lab's flagship facility offers cannabis growers and marijuana-based product-makers fast and reliable results.

"This is a great day for the patients of Nevada who will benefit from medical marijuana," said DigiPath Labs president Todd Denkin. "Our analysis not only helps product producers and dispensaries screen out products with dangerous levels of contaminants, we also quantify the medicinal compounds present in samples, so patients and caregivers can choose products that have been shown to relieve their specific symptoms."

Surprisingly, compulsory cannabis testing is relatively new. The State of Colorado only began requiring product testing a year ago after a series of overdoses on edibles made the news. Washington State did not begin requiring testing for potency, contaminants, moisture and microbiology testing until 2013 when recreational cannabis became legal, even though the medicinal use of marijuana became legal in 1998.

 

Rate this blog entry:
0

BOCA RATON, FL--(Marketwired - May 29, 2015) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, announces positive progress on its High Grade CBD (Cannabidiol) Rich Hemp Oil in vitro studies on various human primary cells with DV Biologics, a leading biological company. In order to assure the public that ETST provides the best High Grade CBD (Cannabidiol) Rich Hemp Oil, we continue to focus on providing the public with sound scientific research and keeping the public informed on the progression of studies being done on our Hemp CBD products. DV Biologics, which is independently testing our ETST High Grade Hemp CBD Oil in vitro on various human primary cells, has informed us of the progression of studies being done. The goals of these studies are to test if ETST High Grade CBD Rich Hemp Oil serves as a neuroprotectant which may help with neurodegenerative disorders.

"Testing compounds in vitro on human cells is difficult. We recently tested various concentrations of ETST High Grade CBD Hemp Oil on various cells to see which concentrations are toxic to cells and noted that the cells grow similarly in concentrations from 1-10 micromolar. This is exciting news as it shows that this product, ETST High Grade CBD Hemp Oil, may be used in varying concentrations without toxicity to different cell types. We are now ready to test whether ETST High Grade CBD Hemp Oil can stop or deter free radical formation that occurs in vitro with brain cells. In order to do so, we will use varying concentrations of ETST Hemp CBD Oil and induce oxidative stress on brain cells. We will then test the cells to see if the ETST Hemp CBD Oil reduces oxidative stress and free radical formation compared to a control cell type that has no ETST High Grade CBD Hemp Oil. We look forward to reporting the full study in the near future," stated Dr. Rafael Gonzalez, Vice President of Research & Development of DV Biologics.

Rate this blog entry:
0
Recent comment in this post - Show all comments
  • Name-Name
    Name-Name says #
    Alert! Shareholders, attention to Earth Science tech, inc alleged fraud etstfraud.com !!!

 

RENO, NV--(Marketwired - May 27, 2015) - INTERACTIVE HEALTH NETWORK (OTC PINK: IGRW), a health company specializing in advances in Supplements for Health and Anti-Aging today announces the formation of three new divisions for focus and execution under the guidance of their recently announced CEO Cesar Vazquez:

  • Indoor Garden/Hydroponics Division
  • Cannabis Oil Nutraceutical Products Division
  • CBD Sports Nutrition Energy Drinks Division

The Indoor Garden/Hydroponics Division will focus on marketing and selling a line of private labeled proprietary products including, but not limited to, light hoods, ballasts, grow bulbs, fans and nutrients. "We plan on launching a very cost effective line of product that leverages my years of real world experience in world class hydroponic products marketed and sold in both our physical retail location and online ecommerce. This market is explosive in growth and in a known need for high quality, but cost effective equipment and optimized nutrients" stated Cesar Vazquez, CEO of Interactive Health Network.

The Cannabis Oil Nutraceutical Products Division will design, produce, market and sell Non THC CBD Capsules and Tinctures, Non THC Oil Capsules and Hemp Oil Topical Creams. "The natural medicinal benefits of CBD and Hemp Oil can benefit many people as an organic option to chemically manufactured alternatives" stated Cesar Vazquez, CEO of Interactive Health Network.

Rate this blog entry:
0
How Accredited Investors Should Follow The Marijuana Trend

This is an exciting time to be an accredited investor in the medical marijuana / cannabis sector, the industry has become legalized in many countries around the world and that trend is only gaining momentum.  To be successful at investing, most sophisticated investors like to follow trends and get invested early while the trend is gaining momentum.  Once you have maximum participation from the retail investing crowd, we can be assured the trend for that sector had pretty much peaked and will soon reverse.

While the last year has been an extreme roller coaster ride for most investors in the cannabis market, we can feel confident that this trend is still at the early stages, well established and on an upward momentum.  The rise and fall in stock prices in the last year was a result of hot money coming in and out of the sector, illiquid markets and tight share structures.  But what we didn't see during that time is the participation from the institutional and professional money crowd. 

Rate this blog entry:

Select Your Language

enzh-CNnlfrdehies

Crowd Funding Campaigns

Featured Listing